About Us

Gifford Bioscience is a preclinical contract research organization (CRO) providing services in receptor occupancy studies, radioligand binding assays and autoradiography.

We are a highly specialised company. This ensures that we have deep experience in our assays, assuring our clients of the highest quality results.

In addition to undertaking standard or custom assays on a client’s sample to our client’s specification, our capabilities include assay design, in-house production of membrane preparations and, through our connection with the University of Birmingham, dosing in vivo or ex vivo and assays requiring human tissue samples. 

We are based at The BioHub Birmingham.

CONTACT US for a chat. We are always happy to discuss potential requirements and assay design.

“KD determination of drug binding to targets, by equilibrium and kinetic measurements, is an essential component of our mechanism of action analyses for drug development.  Gifford Bioscience performs this service using radionuclides with the highest quality, in a cost effective and timely manner.”

Director of Biology, Californian Biotech, June 2019

I was at a loss for how to show loss of a 5-HT7 receptor in a newly created KO rat, given that neither PCR nor antibody-based methods could do so.  Turning to autoradiography saved the day. At every step along the way, you kept me informed as to the status of the preliminary work done prior to the formal experiment, and then the experiment itself. When the final experiment was done, you sent me results in a well documented report that was incredibly detailed and helpful. I WISH that I had these services right here in the US. Pharmacology will never be without the need for documenting receptor number, drug affinities and so on. THANK YOU for making this happen.

Professor, MSU, May 2019

An international customer base:

50% of our clients are from the USA, 31% from Continental Europe.

(2018/19)

Two-thirds of our business is repeat business, coming from scientists we have worked with before.

(H2 2018 / H1 2019)

“We have received outstanding professional service from Gifford Bioscience Limited for our radioligand assays. We receive timely updates at each phase of our project. Moreover, the team at Gifford Bioscience provides its expert advice on the experimental design and analyses, in addition to actually performing the experiments. We strongly recommend Gifford Bioscience to scientists/researchers for their radioligand binding related assays.”

Researcher, US University, March 2019

The Management Team

Dr Andrew Gifford 

Chairman and Chief Scientific Officer

Andrew was previously a Senior Scientist in the radiopharmaceutical development program at Brookhaven National Laboratory, New York. As a Principal Investigator, he has been responsible for the preclinical development of a variety of radiolabeled drugs. Techniques employed in his academic laboratories were primarily radiometric ligand binding and occupancy assays, radiolabeling chemistry and autoradiography.

Andrew is a graduate of Imperial College, London and was awarded his PhD in Pharmacology by the University of St. Andrews.

He is an author of 52 peer-reviewed publications.

Mr Macer Gifford

Managing Director

Macer is a banker by profession. His career has spanned numerous senior roles, including Deputy Group CEO at Ahli United Bank and Group Head of Regional Markets at Standard Chartered PLC.

Macer is a graduate of the London School of Economics and a Sloan Fellow of the London Business School.

Copyright 2008 – 2019 Gifford Bioscience Limited